Market capitalization | $233.48m |
P/E (TTM) P/E ratio | negative |
P/S ratio (TTM) P/S ratio | 1.26 |
P/B ratio (TTM) P/B ratio | 0.55 |
Revenue growth (TTM) Revenue growth | -54.17% |
Revenue (TTM) Revenue | $185.83m |
EBIT (operating result TTM) EBIT | $-21.45m |
Free Cash Flow (TTM) Free Cash Flow | $23.58m |
Cash position | $267.76m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
5 Analysts have issued a OraSure Technologies, Inc. forecast:
5 Analysts have issued a OraSure Technologies, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 186 186 |
54%
54%
|
|
Gross Profit | 81 81 |
53%
53%
|
|
EBITDA | -13 -13 |
120%
120%
|
EBIT (Operating Income) EBIT | -21 -21 |
149%
149%
|
Net Profit | -20 -20 |
136%
136%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
Head office | United States |
CEO | Carrie Manner |
Founded | 2000 |
Website | www.orasure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.